Prostatype Genomics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PROGEN.ST research report →
Companywww.prostatypegenomics.com
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision.
- CEO
- Fredrik Rickman
- IPO
- 2020
- Employees
- 6
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $12.54M
- P/E
- -0.18
- P/S
- 26.07
- P/B
- 0.24
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1186.80%
- Op Margin
- -6401.56%
- Net Margin
- -7196.05%
- ROE
- -104.13%
- ROIC
- -116.07%
Growth & Income
- Revenue
- $594.00K · 198.49%
- Net Income
- $-44,503,000 · -8.41%
- EPS
- $-1.32 · 90.34%
- Op Income
- $-39,080,000
- FCF YoY
- 54.24%
Performance & Tape
- 52W High
- $3.56
- 52W Low
- $0.28
- 50D MA
- $0.82
- 200D MA
- $0.80
- Beta
- 1.52
- Avg Volume
- 219.84K
Get TickerSpark's AI analysis on PROGEN.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PROGEN.ST Coverage
We haven't published any research on PROGEN.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PROGEN.ST Report →